Clinical TrialAlcohol Use Disorder (AUD)LSDRecruiting

LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)

Double-blind, randomised, active placebo-controlled parallel study (n=126) testing two LSD doses (150 µg; second session 150 or 250 µg) versus low-dose active placebo (10 µg) for alcohol use disorder.

Ask Blossom about this trial
Target Enrollment
126 participants
Study Type
Phase II interventional
Design
Randomized, quadruple Blind

Continue exploring

Continue exploring this trial

Move from the registry record to the most relevant public research context.

Compound research: LSDTopic research: Alcohol Use Disorder (AUD)Research in Switzerland

Detailed Description

This is a randomised, double-blind, active placebo-controlled parallel study in specialised addiction treatment centres in Switzerland evaluating LSD for the treatment of moderate to severe alcohol use disorder.

Participants receive two dosing days (treatment arm: 150 µg then 150 or 250 µg; comparator: 10 µg then 10 µg). The primary outcome is percent heavy drinking days at three months after administration; secondary objectives include neurobiological mechanisms.

Study Protocol

Preparation

sessions

Dosing

2 sessions

Integration

sessions

Therapeutic Protocol

Manualized psychotherapy included

Study Arms & Interventions

LSD high dose

experimental

Two-dose LSD regimen with possible escalation in second session (150 µg first; second session 150 µg or 250 µg).

Interventions

  • LSD150 - 250 µg
    via Oral• two sessions• 2 doses total

    Second session 150 µg or 250 µg

Low-dose LSD

active comparator

Active placebo arm receiving low-dose LSD (10 µg) in both sessions.

Interventions

  • LSD10 µg
    via Oral• two sessions• 2 doses total

    10 µg active placebo in both sessions

Participants

Ages
25 – 99
Sexes
Male & Female

Inclusion Criteria

  • Key inclusion criteria:
  • age ≥ 25 years
  • moderate to severe AUD
  • completion of a qualified detoxification for AUD within 30 days prior to screening
  • a minimum of 4 heavy drinking days within the last 30 days before detoxification
  • intention to stop or decrease drinking

Exclusion Criteria

  • Key exclusion criteria:
  • significant alcohol withdrawal symptoms at screening
  • participating or starting in any formal treatment for AUD until completion of visit 9
  • cognitive impairment
  • borderline personality disorder
  • current post-traumatic stress disorder
  • current suicidality or history of a serious suicide attempt
  • significant prodromal symptoms
  • history of a diagnosis of a psychotic or bipolar disorder in subjects or first-degree relatives
  • pregnancy or breast-feeding
  • lack of safe contraception are exclusion criterion for women only

Study Protocol, Arms & Participants

Go Pro to access detailed study protocol timelines, treatment arms, dosing schedules, and participant eligibility criteria.

See Pro Plans

Study Details

  • Status
    Recruiting
  • Phase
    Phase II
  • Type
    interventional
  • Design
    Randomizedquadruple Blind
  • Target Enrollment126 participants
  • Timeline
    Start: 2023-01-01
    End: 2025-01-01
  • Compound
    LSD
  • Topic
    Alcohol Use Disorder (AUD)

Study Team

Sponsors & Collaborators

    Investigators

    • FM
      Felix Mueller

    Locations

    University Hospital of Psychiatry, University of Basel — Basel, Switzerland
    University Hospital of Psychiatry, University of Bern — Bern, Switzerland

    Your Personal Research Library

    Go Pro to save trials, add notes, rate research, and organize custom shelves.

    See Pro Plans